Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab.
Twelve patients who received at least 2 doses of denosumab followed by at least 1 dose of ZA and who had a dual energy X-ray absorptiometry (DXA) scan at the end of denosumab and 1 year after the first dose of ZA were included. We excluded patients with bone cancer or conditions affecting bone metabolism, including hyperparathyroidism, rickets, osteogenesis imperfecta, rheumatologic disorders, fibrous dysplasia, Paget’s disease of bone, untreated hyperthyroidism, chronic kidney disease, liver cirrhosis, malabsorption, ongoing corticosteroid therapy, and aromatase inhibitor use.
There was a significant decline in BMD at the femoral neck within 1 year of the first ZA dose and a non-significant downward trend in the hip and lumbar spine. This trend was more severe in patients with osteoporosis at the time of drug transition. No increase in clinical vertebral fractures was observed. BMD seemed to stabilize in a smaller number of patients who received a second dose of ZA and had a DXA scan 1 year later.
A single dose of ZA administered approximately 6 months after denosumab leads to some BMD loss, mostly within 1 year of ZA administration, particularly in patients with osteoporosis at the time of denosumab discontinuation.
Denosumab is a monoclonal antibody that mimics the action of endogenous osteoprotegerin by binding to and preventing the action of the: receptor activator of nuclear factor-κB ligand (RANKL), thereby inhibiting osteoclasts and preventing bone resorption.[
In our clinical practice, we follow a protocol that attempts to limit total antiresorptive therapy (denosumab+consolidation with ZA) to no more than 5 to 6 years. To transition to ZA, patients should have had stable or improved BMD on denosumab for at least 1 year, but we do not aim to achieve osteopenia prior to initiating consolidation therapy. We routinely evaluate patient response on DXA around 12 months after ZA administration. In this case series, we describe changes in BMD and prevalence of clinical fractures 1 year after transitioning from denosumab to ZA in patients with both osteopenia and osteoporosis at the end of denosumab therapy. We also report observations on BMD changes after a second dose of ZA was given a year later to a smaller subgroup of patients.
This is a retrospective case series of patients with osteoporosis treated with denosumab followed by ZA in the Endocrinology Clinic at an academic medical center. We used the electronic medical records (EMR; Epic 2018 version UI 2; Epic Systems Corp., Verona, WI, USA) to identify patients treated with denosumab followed by ZA between January 1, 2012 (the year denosumab was approved for clinical use in the USA) and June 30, 2020. Eligible patients met the following inclusion criteria: (1) received at least 2 doses of denosumab; (2) followed by at least 1 dose of ZA; (3) underwent DXA at the end of their treatment course with denosumab and approximately 1 year after the first dose of ZA. Patients were excluded if they had bone cancer or other conditions affecting bone metabolism including hyperparathyroidism, rickets, osteogenesis imperfecta, rheumatologic disorders, fibrous dysplasia of the bone, Paget’s disease of the bone, untreated hyperthyroidism, chronic kidney disease, liver cirrhosis, malabsorptive conditions (such as inflammatory bowel disease or celiac disease), and ongoing glucocorticoid or aromatase inhibitor use.
The EMR contains complete demographic, clinical, laboratory, and medication data for all patients seen at our medical center.
Key data elements included patient demographics, height, weight, body mass index (BMI), medical comorbidities, smoking status, alcohol consumption history, DXA measurements and date of each measurement, number of denosumab doses and date of each dose, and number of post-denosumab ZA doses and date of each dose. All doses of denosumab and ZA were administered at our center and dates of administration were extracted from the patients’ EMR.
We also recorded basic laboratory results at the initiation of denosumab, including serum concentrations of calcium, creatinine, parathyroid hormone (PTH), and 25-hydroxy-vitamin D (25[OH]D). Only laboratory values obtained at the core laboratory at our medical center were recorded and used in this analysis to eliminate the bias that could be introduced by the variability between different assays. Calcium and creatinine were determined using Roche Modular P analyzers (Hoffmann-La Roche, Basel, Switzerland). Serum calcium was determined by colorimetric assay (lower detection limit, 0.2 mg/dL; intra-assay coefficient of variation [CV], 0.9%; inter-assay CV, 1.6%; Roche Diagnostics, Mannheim, Germany) and serum creatinine was determined by enzymatic colorimetric assay (lower detection limit, 0.03 mg/dL; intra-assay CV, 0.9%; inter-assay CV, 1.1%; Roche Diagnostics). The 25(OH)D was determined by ARUP Laboratories using the DiaSorin Liaison CIA technology that measured both 25(OH)D2 and 25(OH)D3 (lower detection limit, 0.8 ng/mL; intra-assay CV, 6.7%; inter-assay CV, 6.3%). The laboratory participated in regular Vitamin D External Quality Assessment Scheme performance assessments and passed quality assurance minimal standards. PTH was determined using Roche Modular E170 analyzer using an electrochemiluminescence immunoassay (lower detection limit, 1.2 pg/mL; intra-assay CV, 1.9 %; inter-assay CV, 4.5%; Roche Diagnostics). There were no changes to any of the tests used during the duration of time covered by the study. DXA scans were performed using a Hologic Discovery v12.6.2 instrument (Hologic Inc., Bedford, MA, USA; Center-specific hip and spine least significant change [LSC]=0.020 g/cm2). Areal BMD was measured at the total hip, femoral neck, and lumbar spine (L1-4) and expressed in grams/cm2.
All data were extracted from the patients’ EMR by 1 investigator (TK) and cross-checked by another investigator (ASR).
Statistical analyses were conducted using SAS for Windows, version 9.3 (SAS Institute Inc., Cary, NC, USA) and statistical significance was defined as a
We began by examining patient characteristics and baseline DXA and laboratory results. We also calculated the number of doses of denosumab that each patient received and the duration of time between the last dose of denosumab and the first dose of ZA.
We then examined the change in BMD from baseline (before initiation of denosumab) to the end of the denosumab treatment course and between the end of the denosumab treatment course and the first DXA scan following ZA. We used nonparametric methods (Wilcoxon signed-rank test) to compare these data points. Finally, we used univariable logistic regression to examine the association between changes in BMD and total number of denosumab doses received and between changes in BMD and the duration of time between the last dose of denosumab and the first dose of ZA. Multivariable analyses were not performed due to the small sample size. The institutional review board approved this study.
We identified 12 patients who met the study inclusion and exclusion criteria. A description of our study cohort is presented in
Patients received a median of 5.3 doses of denosumab 6 months apart (range, 3–7 doses). All patients subsequently received at least one dose of ZA (median, 2; range, 1–3 doses). The median duration of time between the last dose of denosumab and the first dose of ZA was 201.5 days (~ 6.7 months).
All patients underwent a DXA measurement in our lab at the end of their denosumab treatment course and another DXA after the first dose of ZA. The median duration of time between the first dose of ZA and the corresponding follow-up DXA scan was 12.0 (1.0) months.
Five patients received a second yearly dose of ZA and had another DXA measurement following the second dose. In these patients, the median duration of time between the first and second doses of ZA was 12.7 (0.4) months. The median duration of time between the second dose of ZA and the corresponding DXA was 12.3 (0.3) months.
None of the patients suffered a clinical fracture while on denosumab. After transition to ZA, 1 patient sustained a distal radial fracture upon a fall. The fracture happened when she lost her balance while trying to sit on a stool and fell down on her extended wrist. She had received 3 doses of denosumab and 1 dose of ZA, the latter being about 6 months prior to the fracture. Her DXA scan about 6 months after the fracture showed a T score of −1.9 at the lumbar spine, −1.0 at the total hip, and −1.6 at the femoral neck. While spine X-rays were not routinely obtained on all patients, 3 patients underwent spine imaging after switching from denosumab to ZA (2 patients underwent thoracic and lumbar spine imaging, and 1 patient underwent lumbar spine imaging only), and no vertebral fractures were identified.
When comparing the changes in measurements between the pre-Dmab and that obtained at the time of completion of denosumab, a statistically significant increase in BMD (
When comparing the DXA scan obtained at the end of denosumab treatment and that obtained after the first dose of ZA, we noted a significant decline in BMD (
On average, within approximately 1 year of switching from denosumab to ZA, patients lost 23% of the BMD gain they had accrued at the lumbar spine while on denosumab, 47% of the BMD gain accrued at the total hip and 54% of the BMD gain accrued at the femoral neck (
In a univariable logistic regression, the decline in BMD between the DXA scan obtained at the end of denosumab and the one obtained after the first dose of ZA was independent of the number of denosumab doses (for change in BMD at the lumbar spine OR=0.48 and
Five individuals received a second dose of ZA and had another DXA scan ~1 year later. We examined the changes in BMD between the DXA that followed the first ZA dose and the one following the second dose.
This case series suggests that patients who receive 1 dose of ZA after treatment with denosumab lose some of the BMD accrued while on denosumab. These results are consistent with previous studies where BMD loss was observed after a single consolidation dose of ZA.[
Our findings also suggest that the bone loss at the total hip and spine is much larger in patients who remained osteoporotic while on denosumab. This finding might present an argument in favor of ensuring patients’ BMD is in the osteopenia range on denosumab before switching them to ZA. It is worth making a note here of a recent study by Anastasilakis that randomized 57 women previously treated with denosumab for osteoporosis to another 2 doses of denosumab versus a single dose of ZA. Twelve months after randomization, an equal but non-significant increase in the lumbar spine and femoral neck BMD was seen in both groups, despite higher levels of bone turnover markers (BTMs) in the group randomized to ZA.[
One possible explanation for the observed bone loss when switching from denosumab to ZA lies in the fact that bisphosphonates need “open bone surfaces” to adhere to in order to exert their antiresorptive action.[
Alternatively, it may be attractive to delay ZA by more than 6 months after the last dose of denosumab to allow for some recovery of bone turnover and for the drug to adhere better to bone surfaces. Horne et al. [
It is important to acknowledge potential limitations of this work. First, our sample size was small and this may explain the lack of statistical significance in some of our analyses. Notably however, while our analyses of BMD changes at the lumbar spine and hip did not reach statistical significance, the trends were comparable to previous studies that did achieve statistical significance.[
In conclusion, a single dose of ZA given approximately 6 months after long-term denosumab therapy leads to a loss of a portion of the BMD gained with denosumab, and much of this loss seems to occur within 1 year of ZA, particularly in patients who are osteoporotic at the time of transition. Furthermore, limited data suggest that the loss in BMD may plateau after a second dose of ZA. However, larger and longer-term studies with careful evaluation of fracture risk are needed to provide a definitive answer on the safety and best approach to post-denosumab consolidation therapy with ZA.
The authors received no financial support for this article.
The study was reviewed and approved by the Institutional Review Board for human subjects’ research.
No potential conflict of interest relevant to this article was reported.
Bone mineral density (BMD) and T-score measurements in 5 patients who received 2 doses of zoledronic acid. Each line represents an individual patient. DXA, dual energy X-ray absorptiometry; Pre-Dmab, DXA scans prior to initiation of denosumab; Post-Dmab, DXA scans after completion of treatment with denosumab; Post-ZA1, DXA scans after the first dose of zoledronic acid; Post-ZA2, DXA scans after the second dose of zoledronic acid.
Patient characteristics
Characteristics | Value (N=12) |
---|---|
Age (yr), median (IQR) | 76.8 (8.8) |
| |
Sex (female) | 12 (100.0) |
| |
Race (white) | 12 (100.0) |
| |
BMI (kg/m2), median (IQR) | 21.9 (4.5) |
| |
25(OH)D (ng/mL), median (IQR) | 37.5 (13.0) |
| |
Calcium (mg/dL), median (IQR) | 9.8 (0.7) |
| |
PTH (pg/mL), median (IQR) |
40.1 (3.9) |
| |
Creatinine (mg/dL), median (IQR) | 0.7 (0.2) |
| |
Smoking | |
Current smoker | 1 (8.3) |
Previous smoker | 4 (33.3) |
| |
Alcoholic drinks per week, median (IQR) | 1 (1.5) |
| |
Trauma | |
Presence of low-trauma fracture before Dmab | 2 (16.7) |
Presence of low-trauma vertebral fracture before Dmab | 1 (8.3) |
| |
BMD (gm/cm2), median (IQR) | |
Lumbar spine | 0.82 (0.03) |
Total hip | 0.69 (0.05) |
Femoral neck | 0.59 (0.02) |
| |
Treatment received | |
Received bisphosphonate before Dmab | 7 (58.3) |
Bisphosphonate washout before Dmab (yr), median (IQR) |
4 (2.5) |
No. of Dmab doses, median (IQR) | 5.3 (1.2) |
No. of ZA doses, median (IQR) | 2 (0.3) |
Patients with osteoporosis at time of transition to ZA | 6 (50.0) |
Lag time between last dose of Dmab and first dose of ZA (days), median (IQR) | 201.5 (31.3) |
The data is presented as median (IQR) or number (%).
PTH available in 5 patients.
Baseline BMD in 9.
Bisphosphonate washout applies to 7 patients who received bisphosphonate before Dmab.
IQR, interquartile range; BMI, body mass index; 25(OH)D, 25-hydroxy-vitamin D; PTH, parathyroid hormone; BMD, bone mineral density; Dmab, denosumab; ZA, zoledronic aid.
Changes in bone density measurements over time
DXA measurement site | DXA time | ||
---|---|---|---|
Pre-Dmab (N=9) | Post-Dmab (N=12) | Post-ZA (N=12) | |
BMD (g/cm2) | |||
Lumbar spine | 0.82 (0.03) | 0.90 (0.15) |
0.87 (0.08) |
Total hip | 0.69 (0.05) | 0.75 (0.04) | 0.72 (0.08) |
Femoral neck | 0.59 (0.02) | 0.63 (0.06) |
0.62 (0.05) |
The data is presented as median (interquartile range).
Lumbar spine measurement excluded in 1 patient due to severe degenerative changes.
Statistically significant increase from pre-Dmab,
Statistically significant decrease from post-Dmab,
DXA, dual energy X-ray absorptiometry; Pre-Dmab, DXA scans prior to initiation of denosumab; Post-Dmab, DXA scans after completion of treatment with denosumab; Post-ZA, DXA scans after the first dose of zoledronic acid; BMD, bone mineral density.
Relative changes in BMD upon switching from Dmab to ZA
Site | All patients | Patients with osteopenia at end of Dmab | Patients with osteoporosis at end of Dmab | ||
---|---|---|---|---|---|
|
|
| |||
Median BMD gain on Dmab (g/cm2) | Median BMD loss after switching to ZA (g/cm2) | Percent of median BMD gain that is lost with ZA | Percent of median BMD gain that is lost with ZA | Percent of median BMD gain that is lost with ZA | |
Lumbar spine | 0.048 | 0.011 | 23% | 7% | 61% |
| |||||
Total hip | 0.034 | 0.016 | 47% | 43% | 220% |
| |||||
Femoral neck | 0.048 | 0.026 | 54% | 49% | 37% |
BMD, bone mineral density; Dmab, denosumab; ZA, zoledronic aid.